On September 27th, Sanofi announced that Dapitumab Injection has been approved by the China National Medical Products Administration for use in adult patients with chronic obstructive pulmonary disease who have elevated blood eosinophils and poor control. This approval is based on the results of two milestone Phase III clinical trials, which demonstrate the efficacy of Dapidor&Co; reg; (Once every two weeks) significantly reduced acute exacerbations and improved lung function. This approval precedes the US FDA. Compared with placebo combined with the best standard inhalation therapy (triple therapy, if ICS contraindications are present, dual bronchodilators are allowed), dabigatur& reg; After 52 weeks of treatment, the annualized rates of moderate to severe acute exacerbation of chronic obstructive pulmonary disease decreased by 30% and 34%, respectively.